REQUEST A DEMO
总计
USD $0.00
搜索更多公司

Adagene Inc. (中国)

主营业务: 医药制剂制造
全名: Adagene Inc. 公司更新日期: 2024.08.27
购买我们的报告为这家公司 USD 29.95 最近财务数据:2023 可有的: 英语 & 中文 下载示例的报告

The Company, together with its subsidiaries, are principally engaged in research, development and production of monoclonal antibody drugs for cancers.
The Company is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Its platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by The Company s immunotherapy pipeline. These features enable its novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. The Company has pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. The Company aims to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology.
The Company operates and manages it business as a single segment.
HISTORY
2011 The Company is a limited liability company incorporated in the Cayman Islands on February 25, 2011.
In December 2011, the Company established Adagene (Hong Kong) Limited, or Adagene Hong Kong, a wholly-owned subsidiary incorporated under the laws of Hong Kong, as its intermediary holding company.
2017 In September 2017, the Company established a wholly-owned subsidiary in the state of Delaware, the United States, Adagene Incorporated, to conduct its research and development activities in the United States to facilitate the discovery and development of product candidates and expand its global presence, the Company has further incorporated several subsidiaries overseas, such as Australia, Singapore and Switzerland.
2021 The Company s ADSs have been listed on the Nasdaq Global Market since February 9, 2021 under the symbol “ADAG.”
2024 On March 29, 2024, the Company entered into a sales agreement with Leerink Partners LLC, under which the Company may offer and sell its ordinary shares in the form of ADSs, having aggregate gross proceeds of up to US 100.0 million, from time to time through it as its sales agent in its at-the-market equity offering program.

总部
4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province
苏州; 江苏; 邮编: 215123

联系方式: 购买Adagene Inc.报告以查看信息。

网站: http://www.adagene.com

基本信息
员工总数:
购买Adagene Inc.报告以查看信息。
流通股:
购买Adagene Inc.报告以查看信息。
财务审计师:
购买Adagene Inc.报告以查看信息。
成立日期:
2011
主要管理人员
购买此报告以查看信息。
Chairman
购买此报告以查看信息。
Chief Financial Officer
购买此报告以查看信息。
Chief Technology Officer
购买此报告以查看信息。
Senior Vice President
购买此报告以查看信息。
Senior Vice President
所有权明细
购买此报告以查看信息。
10.9%
购买此报告以查看信息。
9.7%
购买此报告以查看信息。
9%
购买此报告以查看信息。
8.7%
购买此报告以查看信息。
8.7%
下属公司
Adagene Incorporated (美国)
100%
Adagene Pte. Ltd. (新加坡)
100%
Adagene (Hong Kong) Limited (中国香港特别行政区)
公司业绩
图表中的财务价值可在之后获得Adagene Inc.报告购买。
寻找的不仅仅是一个公司的报告吗?

EMIS公司简介是一个更大的信息服务的一部分,它结合了公司,行业和国家数据和分析在超过125个新兴市场.

请求EMIS服务的演示
主要财务重点
年增长百分比对于以当地货币近两年USD。绝对财务数据包含在购买报告中。
营业利润
-283.85%
净利润(亏损)
-314.02%
总资产
-25.51%
权益总额
-31.65%
股本收益率
-25.1%
负债股权比率
6.17%
速动比率
-0.9%
现金比率
-0.88%

查看更多信息, 申请试用

购买这家公司报告
需要定期访问公司,行业或国家/地区的信息吗?